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Abstract
 
Introduction
We estimated the prevalence of multiple sclerosis (MS) 
in 3 large geographic areas in the southern, middle, and 
northern United States.
 
Methods
The primary data source was medical records from 
office visits to private neurologists’ practices or to neurol-
ogy departments in tertiary care facilities during a 3-year 
period. Additional data sources included patient advocacy 
groups, nursing homes, and general practitioners.
 
Results
Three-year US age-adjusted prevalence estimates for 
the study areas varied substantially. The prevalence 
was lowest (47.2 per 100,000 population) in the Texas 
study area (33°30′ north latitude), intermediate (86.3 per 
100,000 population) in the Missouri study area (39°07′ 
north latitude), and highest (109.5 per 100,000 population) 
in the Ohio study area (41°24′ north latitude). The geo-
graphic differences remained strong after age-adjustment 
to the world standard population. The inverse association 
between UV light exposure and MS prevalence estimates 
was consistent with this observed latitude gradient. In all 
3 areas, MS prevalence was highest among women, people 
aged 40 to 59 years, and non-Hispanics.
 
Conclusion
These results provide necessary prevalence estimates 
for community cluster investigations and establish base-
line estimates for future studies to evaluate temporal 
trends in disease prevalence.
Introduction
 
Multiple sclerosis (MS) is an inflammatory demyelinat-
ing disease of unknown origin; it affects more than 1 mil-
lion people worldwide (1) and disproportionately affects 
women and whites (2). Approximately 85% of affected 
people have a relapsing-remitting course, characterized 
by an unpredictable course of exacerbations and remis-
sions (3). Ultimately, most patients become disabled and 
may or may not have superimposed relapses (secondary 
progressive MS) (3,4). Approximately 15% of patients have 
primary progressive MS, in which the condition worsens 
gradually from disease onset and is not associated with 
relapses (5).
 
The ability of a public health agency to enumerate cases 
and determine whether an excess of cases is present in a 
particular community is compromised by the lack of MS 
registries, the range of disease severity, which can affect 
ascertainment, and unknown background prevalence esti-
mates. Prevalence estimates for MS vary from 58 to 95 per 
100,000 population in the United States (6-8). In the past 
25 years, prevalence studies of specific US locales have 
produced a range of estimates (9), up to 177 per 100,000 
population in Olmstead County, Minnesota (10). Our goal 
was to determine MS prevalence estimates for 3 areas 
in the southern, middle, and northern United States to 
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be used as regional comparisons for community-specific 
investigations of MS prevalence and as baseline estimates 
for studies of temporal trends in prevalence.
Methods
Study areas
 
The areas we studied were Lorain County, Ohio; the 
cities of Sugar Creek and Independence, Missouri; and 19 
counties surrounding Lubbock, Texas. Lorain County (pop-
ulation 284,664) was included in this study because the 
community had expressed concerns about the frequency 
of MS in the city of Wellington (population 3,171) and the 
possible health risks of proximity to an iron foundry and 
plastics company. Results from a previous cluster investi-
gation in Wellington identified 27 cases of MS for a crude 
point prevalence estimate of 651 per 100,000 persons, but 
this assessment was limited by the lack of appropriate US 
comparison prevalence estimates for Ohio (11).
 
Another community, Sugar Creek, expressed similar 
concerns about a perceived excess of MS cases and was 
near an oil refinery that operated in the area from 1904 
to 1982 (12). Although refinery operations ceased in 1982, 
portions of the site are still used as a light-oil petroleum 
product marketing terminal, a pipeline facility, and an 
asphalt receiving and processing center. Because of the 
small size of Sugar Creek (population 9,915), the adjacent 
city of Independence (population 110,884) was included for 
comparison.
 
The 19-county area around Lubbock (population 424,916) 
was proposed to provide MS prevalence estimates for 
comparison with a previous MS cluster investigation 
conducted in El Paso, Texas (13). In all 3 previous cluster 
investigations, the lack of an appropriate comparison for 
MS prevalence estimates precluded an assessment of the 
true effect of the disease.
Case ascertainment
 
The primary data source for case ascertainment was 
medical records from the offices of neurologists practicing 
in the study area or in contiguous areas or from the neurol-
ogy departments of local hospitals. In Ohio, this included 
offices and hospitals in Lorain and Cuyahoga counties, 
including the Cleveland Clinic, 8 private neurologists, and 
5 hospitals. In Missouri, this included offices and hospitals 
in Clay and Jackson counties, Missouri, and Johnson and 
Wyandotte counties, Kansas, including 12 private neu-
rologists and 8 hospitals that provided neurologic care. In 
Texas, the Texas Tech University Medical System and 8 
private neurologists provided neurologic specialty services 
and care for the study area.
 
Residence was determined by the address in the patient’s 
medical record. Records were included if patients had an 
office visit from January 1, 1998, through December 31, 
2000, and had the following International Classification of 
Disease, 9th Revision, codes or corresponding conditions: 
MS (340), other demyelinating diseases (341.8-341.9), 
transverse myelitis (323.9), and optic neuritis (377.3).
 
We used additional data sources to evaluate the com-
pleteness of case ascertainment, including patient advo-
cacy groups (the National Multiple Sclerosis Society), 
nursing homes, general practitioners, and death certifi-
cates. Self-reports were not actively sought; however, if 
people with potential cases identified themselves to study 
personnel, they were asked to provide the name of their 
treating physician. Similarly, treating physicians were 
identified for any potential cases identified through MS 
advocacy groups or nursing homes. If not already included 
in the surveillance effort, all medical records that met the 
inclusion criteria were abstracted from the treating phy-
sician’s office. This study was approved by institutional 
review boards in each study area and by the Centers for 
Disease Control and Prevention.
Case verification
 
Trained abstractors, who were supervised by the project 
investigators and neurologists, used a standard form that 
included history of relapses, neurologic examination find-
ings, and results of evoked potentials, cerebrospinal fluid 
examination, and magnetic resonance imaging of the brain 
and cervical spine. Abstractors also recorded sex, race/
ethnicity, occupation, family history of MS, country/state 
of birth, treating physician’s MS diagnosis, criteria used 
to determine diagnosis, and dates of symptom onset and 
diagnosis. Individual identifiers (name, address, and Social 
Security number) were recorded to ensure accurate case 
counts and to avoid duplicate counting from other sources.
 
The abstracted records of all patients with potential 
MS cases were evaluated by reviewing neurologists in 
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each study area according to the Poser criteria (14). We 
chose the Poser criteria because they were the criteria in 
use during the period evaluated. Each case was classified 
as definite (clinical or laboratory supported) or probable 
(clinical or laboratory supported) MS. We also considered 
2 additional disease classification categories. The category 
of presumptive MS was used for cases for which data 
were insufficient to satisfy clinical criteria but for which a 
diagnosis seemed correct after review, and the category of 
unknown was used when data were insufficient to deter-
mine the presence or absence of MS. If necessary to clas-
sify a specific case, the neurologist directed the abstractor 
to collect additional information. We used only definite 
and probable categories to calculate prevalence for this 
analysis.
Exposure to UV radiation
 
To explore the geographic difference in MS prevalence 
estimates, we evaluated the differences in UV radiation 
exposure between study regions. Patterns of exposure to 
UV radiation are similar to patterns of distribution of MS 
in some areas, which suggests a possible contribution to 
MS risk (15,16). We used archived data from the National 
Weather Service’s UV Index Forecast averaged for 1997 
through 2001 for sites near our study areas (17). The UV 
Index Forecast is the scaled erythemal (skin reddening) 
dose rate integrated over the UVB and UVA spectral 
bands. The data were summarized according to World 
Health Organization categories from low to extreme. 
The UV data locations (and their approximate distance 
from the respective study areas) were Cleveland, Ohio 
(29 miles); Saint Louis, Missouri (249 miles); and Dallas, 
Texas (347 miles). Each of these surrogate locations was in 
the same state and at approximately the same latitude as 
its respective study area.
Data analysis
 
We calculated age- and sex-specific period prevalence 
estimates by using the definite and probable MS cases 
ascertained from 1998 through 2000 as the numerator and 
the 2000 census counts for the study areas as the denomi-
nator. Overall prevalence estimates for each area were 
directly race-adjusted to the US 2000 race/ethnicity dis-
tribution and age-adjusted to the US 2000 and the world 
standard populations (18,19). The differences between 
strata-specific prevalence estimates were evaluated by 
assuming a Poisson distribution. We used SAS version 9.0 
(SAS Institute, Inc, Cary, North Carolina) for statistical 
analyses. To evaluate latitude, regression analysis was 
used to estimate the increase in MS prevalence for a unit 
increase (degree) in latitude.
Results
 
All practicing neurologists in the 3 study areas partici-
pated and provided medical records for review. Abstractors 
screened 1,434 medical records, and 670 records did not 
meet the screening criteria for date of office visit or place 
of residence. The remaining 764 records were abstracted 
and reviewed by the study neurologists to confirm MS. 
Of these, 608 (80%) were classified as definite or prob-
able MS. A small number of patients (7 in Texas, 17 in 
Missouri, and 4 in Ohio) had symptoms that suggested 
MS, but data were insufficient to satisfy the clinical cri-
teria. These cases were not included in the prevalence 
estimates. In Missouri, approximately 20% of reviewed 
records were captured from tertiary care facilities with MS 
specialization facilities, compared with 54% in Texas and 
57% in Ohio.
 
Overall prevalence estimates for the study areas varied 
greatly; the prevalence was lowest in Texas (33°30′ north 
latitude), followed by Missouri (39°07′ north latitude), and 
highest in Ohio (41°24′ north latitude). Prevalence esti-
mates changed slightly after age-adjustment to the US or 
world standard populations, but the monotonic prevalence 
gradient remained consistent with the increase in US age-
adjusted prevalence per degree increase in latitude of 7.7 
(95% confidence interval [CI], −2.1 to 17.5) per 100,000 
population. For US age-adjusted estimates, the difference 
in prevalence per 100,000 population between Texas and 
Missouri was 39 (95% CI, 21-57), and the difference in 
prevalence per 100,000 between Missouri and Ohio was 
23 (95% CI, 3-54).
 
Race-adjusted prevalence estimates for the 3 areas 
showed a pattern similar to the age-adjusted estimates, 
although the difference in race-adjusted prevalence 
between Missouri and Ohio was only 16 (95% CI, −2.6 
to 35.1) per 100,000 (Table). Prevalence was higher in 
non-Hispanic whites than in other racial/ethnic groups. 
In Texas, the difference in prevalence estimates between 
non-Hispanic whites and Hispanics was 45 (95% CI, 34-
56) per 100,000. In Ohio, the difference in prevalence esti-
mates between these 2 groups was 43 (95% CI, 8-79) per 
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100,000. The prevalence was lower in non-Hispanic blacks 
than in non-Hispanic whites in Texas, a difference of 34 
(95% CI, 14-54) per 100,000, but the prevalences in these 
groups were not significantly different in Ohio. Data from 
Missouri concerning prevalence in minority populations 
were too sparse to draw any conclusions, possibly because 
of the smaller size of this study population. The MS preva-
lence was much higher in women than in men (4.1, 3.9, 
and 2.8 times as high in women in Texas, Missouri, and 
Ohio, respectively) (Table).
 
When evaluating the UV data, 46% of days were classi-
fied as high to extreme UV exposure in Texas (the south-
ernmost area with the lowest prevalence of MS), compared 
with 29% of days for Missouri (middle latitude) and 21% 
of days for Ohio (northern latitude) (P < .001, Cochran-
Armitage test for trend).
Discussion
 
In the United States, reported prevalence estimates 
for MS vary widely, which may reflect differences in 
ascertainment methods or in the underlying population 
structure (18,19). To the best of our knowledge, this is the 
first study to simultaneously estimate population-based 
MS prevalence in 3 US communities by using the same 
ascertainment and case-verification methods. Our preva-
lence estimates reflect the range of estimates previously 
observed and support the reported geographic heterogene-
ity of MS prevalence in the United States and elsewhere 
(20,21). The northernmost area in our study had the 
highest MS prevalence, and the southernmost area had 
one of the lowest MS prevalences observed in recent US 
studies. Although the Lubbock area had a high proportion 
of Hispanics (a group in which the prevalence of MS may 
be low or underreporting may be high) (22), the prevalence 
for non-Hispanic whites was only 56.0 per 100,000.
 
Higher prevalence estimates were observed among 
whites than among blacks in the Texas area, which is 
similar to national survey data in the United States 
(6-8). In the Ohio area, MS prevalence estimates were 
similar for non-Hispanic whites and non-Hispanic blacks. 
Race/ethnicity was undetermined for 45 (14%) of the MS 
patients in Ohio. Even if all of these patients were non-
Hispanic whites, the resulting prevalence estimates per 
100,000 would be 117.9 for non-Hispanic whites, compared 
with 90.9 for non-Hispanic blacks. These revised estimates 
do not significantly differ, and the absolute difference in 
prevalence estimates by race for this area was still much 
lower than that observed in the Texas area or in previous 
US studies. The reason for this difference between study 
areas is unknown, and unfortunately, racial heterogene-
ity in the third study area was insufficient to explore this 
issue further. The difference in prevalence estimates for 
Hispanics in Texas and Ohio is also noteworthy, but the 
reason is unclear.
 
A previous report noted that if incidence studies were 
age-adjusted to a common population, latitude was not 
associated with incidence (18). This analysis was lim-
ited to 22 incidence studies, none from the United States. 
Prevalence data were less affected by age adjustment; 
latitude associations remained after adjustment to the 
world population. These analyses included only prevalence 
studies from a single area in the United States at approxi-
mately 44° north latitude, and all studies were grouped 
by 10° latitude intervals. Furthermore, racial and ethnic 
differences in populations studied were not considered. 
Our results, even after age-adjustment, demonstrate a 
strong gradient within a small range in latitude, approxi-
mately 33° to 41° north latitude, with a prevalence ratio 
of 2.32 between the northern (Ohio) and southern (Texas) 
regions, similar to the relative risk of MS observed in US 
veterans according to where they lived when they joined 
the military (23). However, this study and others suggest 
that the latitude gradient in the United States and other 
parts of the world is not as steep as previously suspected. 
These studies also suggest an increasing risk of MS in 
nonwhites, which emphasizes that prevalence estimates 
must be adjusted for sex and race (20,24).
 
The geographic distribution of MS is interpreted by 
some researchers as reflecting differences in the distribu-
tion of genetically susceptible populations, as determined 
by racial and ethnic backgrounds (25,26). Our study areas 
showed a geographic gradient even when we restricted the 
analysis to non-Hispanic whites, but we could not charac-
terize patient ancestry. Migration studies suggest an asso-
ciation between geography and MS risk (27,28), but unless 
migration patterns were differential between regions, this 
association would not explain our findings.
 
Differences in environmental risk could also influence 
geographic variation in MS prevalence, and some stud-
ies have postulated that UV exposure could influence 
this variation. The geographic gradient in MS prevalence 
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in Australia correlates strongly with UV exposure (16). 
Similarly, in a US case-control study, high levels of resi-
dential and occupational sunlight exposure were inversely 
associated with risk of MS (15). Our data support this 
inverse association between UV exposure and MS preva-
lence, although the mechanism by which UV exposure may 
influence MS risk is unknown (16). UV exposure is only 1 
of several factors that could explain the epidemiologic fea-
tures of MS, but such questions cannot be answered with 
this ecologic analysis.
 
This project had several strengths. First, the application 
of consistent case-finding and case-verification method to 
3 geographically distinct areas allowed us to evaluate the 
previously reported latitude gradient for MS. We captured 
age- and sex-specific prevalence estimates, which allows 
adjusted comparisons with MS prevalence studies world-
wide. Second, we captured race/ethnicity data for 89% of 
cases, allowing for an evaluation of racial/ethnic differ-
ences in MS prevalence. Finally, medical records review 
usually provided sufficient data to verify MS diagnosis 
according to rigid clinical criteria. This cost- and time-
effective approach to data gathering had high specificity 
for identifying MS cases.
 
Although our use of a rigid case definition enhanced spec-
ificity, it may have reduced sensitivity of ascertainment. 
Although abstracted records typically included extensive 
case histories, some borderline cases would have required a 
clinical visit for accurate diagnosis, and some records may 
have contained insufficient information if patients had 
recently changed physicians. For the 3 areas combined, 
however, less than 4% of reviewed records strongly sug-
gested MS but data were insufficient to classify them as 
definite or probable. If the final case counts included all 
these records, the crude prevalence estimates per 100,000 
would be 44 in Texas, 102 in Missouri, and 114 in Ohio.
 
Because the primary data source was neurologists’ prac-
tices and neurology departments of tertiary care facilities, 
some cases were probably missed (29), particularly among 
the small proportion of patients with benign disease or 
relapsing-remitting MS in sustained remission. These 
patients may not regularly seek neurologic care and may 
not have been captured during our study period, and a 
longer study period may have captured less severe MS 
cases. Few cases were captured through general physi-
cians because we did not actively pursue this source. We 
may have also missed MS patients who did not have access 
to the health care system. The sites differed with respect 
to the proportion of private neurology practices versus 
tertiary-care facilities as the source of case ascertainment, 
which could lead to differences in the completeness of case 
ascertainment. Regardless of differences in the medical 
communities serving the respective areas, however, both 
of these sources are considered the most appropriate data 
sources (29). Where estimates of MS prevalence exist for 
regions of similar latitude, our prevalence estimates are 
similar (29,30).
 
Our study established the feasibility of using a uniform 
method for case ascertainment in different geographic 
regions and demonstrated that the distribution of MS var-
ies with respect to geography, sex, and race/ethnicity. It pro-
vides necessary background prevalence estimates for clus-
ter investigations while establishing baseline estimates for 
future studies evaluating temporal trends in prevalence.
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Table
Table. Cases of Multiple Sclerosis and Respective Strata-Specific and Adjusted Prevalence Estimates for 3 Areas, 1998-2000
Characteristic
Texas (Lubbock and 19-County 
Surrounding Area) Missouri (Independence and Sugar Creek) Ohio (Lorain County)
No. of 
Casesa Population
Prevalence per 
100,000  
(95% CI)
No. of 
Casesa Population
Prevalence per 
100,000 (95% CI)
No. of 
Casesa Population
Prevalence per 
100,000 (95% CI)
Sex
Women 147 214,2 8. (8.0-80.) 8 2,870 1.8 (109.-
19.2)
27 14,017 1.4 (142.2-
184.)
Men  210,81 1. (11.-2.1) 20 7,929 4. (21.-.2) 8 19,47 9.4 (4.4-72.4)
Age, y
<0 19 201,420 9.4 (.7-14.7) 4 47,8 8.4 (2.4-21.7) 10 11,24 8. (4.0-1.9)
0-9  7,282 7. (9.7-80.9) 1 17,244 7.4 (40.-129.1) 4 42,48 80.0 (2.4-107.)
40-49 9 7,29 10.1 (78.-
12.9)
40 18,172 220.1 (1.9-
299.7)
97 4, 212.4 (19.-
2.)
0-9 49 40,89 119.9 (88.7-
18.)
4 14,078 241. (17.-
7.0)
102 ,274 0. (24.8-
7.2)
0-9 17 0,7 .4 (2.-88.7) 11 10,247 107. (.-192.) 40 21,088 189.7 (129.7-
249.7)
≥70 4 7,40 10.7 (2.9-27.4) 4 1,7 29.9 (7.9-7.8) 7 2,900 142.9 (9.9-189.9)
Unknown 1 NC NC 0 NC NC 0 NC NC
Race/ethnicity
Hispanic 1 142,448 11.2 (.4-18.2) 0 2,40 NC 11 19,42 .0 (21.-90.7)
Non-Hispanic 
white
140 249,882 .0 (47.1-.1) 104 108,97 9. (77.9-11.) 242 24,88 99.4 (8.-112.2)
Non-Hispanic 
black
 27,17 22.1 (8.1-48.1) 1 2,984 NC 22 24,19 90.9 (2.1-129.7)
Other/
unknown
20 NC NC 1 ,408 NC 4 NC NC
 
Abbreviations: CI, confidence interval; NC, not calculable. 
a Cases include diagnoses of definite or probable MS according to the Poser 198 criteria (14). 
b Directly race-adjusted to the 2000 US population. Cases with missing/unknown data on race/ethnicity (20 in Texas, 1 in Missouri, and 4 in Ohio) were not 
included in specific strata for race/ethnicity prevalence. 
c Directly age-adjusted to the 2000 US population. 
d Directly age-adjusted to the 2000 world population. To calculate age-adjusted prevalence, cases with missing data on age (1 in Texas and  in Ohio) were 
assumed to be in the age group with highest prevalence, 0-9 years.
(Continued on next page)
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Characteristic
Texas (Lubbock and 19-County 
Surrounding Area) Missouri (Independence and Sugar Creek) Ohio (Lorain County)
No. of 
Casesa Population
Prevalence per 
100,000  
(95% CI)
No. of 
Casesa Population
Prevalence per 
100,000 (95% CI)
No. of 
Casesa Population
Prevalence per 
100,000 (95% CI)
Crude overall 182 424,91 42.8 (.8-49.) 10 120,799 87.7 (71.-10.4) 20 284,4 112.4 (99.8-12.0)
Race- 
adjustedb
12 NC 44.2 (7.2-1.2) 10 NC 72. (7.2-88.0) 27 NC 88.9 (78.1-99.7)
US age- 
adjustedc
182 NC 47.2 (40.-4.1) 10 NC 8. (9.8-102.8) 20 NC 109. (97.-121.)
World age-
adjustedd
182 NC 9.9 (4.0-4.7) 10 NC 70. (.9-84.) 20 NC 8. (7.8-9.2)
 
Abbreviations: CI, confidence interval; NC, not calculable. 
a Cases include diagnoses of definite or probable MS according to the Poser 198 criteria (14). 
b Directly race-adjusted to the 2000 US population. Cases with missing/unknown data on race/ethnicity (20 in Texas, 1 in Missouri, and 4 in Ohio) were not 
included in specific strata for race/ethnicity prevalence. 
c Directly age-adjusted to the 2000 US population. 
d Directly age-adjusted to the 2000 world population. To calculate age-adjusted prevalence, cases with missing data on age (1 in Texas and  in Ohio) were 
assumed to be in the age group with highest prevalence, 0-9 years.
Table. (continued) Cases of Multiple Sclerosis and Respective Strata-Specific and Adjusted Prevalence Estimates for 3 Areas, 
1998-2000
